Eray Goekkurt

9.3k total citations · 1 hit paper
100 papers, 2.3k citations indexed

About

Eray Goekkurt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Eray Goekkurt has authored 100 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Oncology, 68 papers in Pulmonary and Respiratory Medicine and 35 papers in Surgery. Recurrent topics in Eray Goekkurt's work include Gastric Cancer Management and Outcomes (56 papers), Colorectal Cancer Treatments and Studies (37 papers) and Gastrointestinal Tumor Research and Treatment (27 papers). Eray Goekkurt is often cited by papers focused on Gastric Cancer Management and Outcomes (56 papers), Colorectal Cancer Treatments and Studies (37 papers) and Gastrointestinal Tumor Research and Treatment (27 papers). Eray Goekkurt collaborates with scholars based in Germany, United States and Switzerland. Eray Goekkurt's co-authors include Jan Stoehlmacher, Jörg T. Hartmann, Wolf O. Bechstein, Torsten Liersch, Florian Lordick, Heidi Schwarzenbach, Gunnar Folprecht, Klaus Pantel, Jürgen Weitz and Thomas Gruenberger and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Eray Goekkurt

96 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

2009 671 citations Gunnar Folprecht, Thomas Gruenberger et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Eray Goekkurt

Since Specialization

Citations

This map shows the geographic impact of Eray Goekkurt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eray Goekkurt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eray Goekkurt more than expected).

Fields of papers citing papers by Eray Goekkurt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eray Goekkurt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eray Goekkurt. The network helps show where Eray Goekkurt may publish in the future.

Co-authorship network of co-authors of Eray Goekkurt

This figure shows the co-authorship network connecting the top 25 collaborators of Eray Goekkurt. A scholar is included among the top collaborators of Eray Goekkurt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eray Goekkurt. Eray Goekkurt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma 2024 ·JAMA Network Open ·Peter Thuss‐Patience, (unknown), Eray Goekkurt, M. Stahl, Albrecht Kretzschmar, Thorsten Oliver Götze, (unknown), Peter Reichardt, Frank Kullmann, Daniel Pink, (unknown), (unknown), Axel Hinke, Christoph Schultheiß, Lisa Paschold, Alexander Stein, Mascha Binder	9
2	Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415) 2023 ·BMC Cancer ·Sylvie Lorenzen, (unknown), Claudia Pauligk, Eray Goekkurt, (unknown), Jorge Riera Knorrenschild, Gerald Illerhaus, Tobias Dechow, Markus Moehler, (unknown), Daniel Pink, M. Stahl, (unknown), Thorsten Oliver Goetze, Salah‐Eddin Al‐Batran	5
3	1623P Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study 2023 ·Annals of Oncology ·Dirk Arnold, Eray Goekkurt, Alexander Stein, Uwe M. Martens, (unknown), Guy Ungerechts, Houra Loghmani, Matt Coffey, Richard Trauger, Thomas C. Heineman	5
4	Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice 2022 ·Oncology Research and Treatment ·Anke Reinacher‐Schick, Dirk Arnold, Marino Venerito, Eray Goekkurt, (unknown), Thomas Seufferlein	1
5	P-49 GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – safety and preliminary response results 2022 ·Annals of Oncology ·(unknown), Dirk Arnold, Alex Stein, Eray Goekkurt, Ute Martens, Houra Loghmani, (unknown)	1
6	1203O FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase II Moonlight trial of the AIO 2022 ·Annals of Oncology ·Sylvie Lorenzen, Peter Thuss‐Patience, (unknown), Jorge Riera Knorrenschild, Volker Heinemann, Eray Goekkurt, (unknown), Thomas J. Ettrich, Kim Barbara Luley, (unknown), Udo Lindig, Stefan Angermeier, Oliver Waidmann, Daniel Pink, Claus Bolling, (unknown), Claudia Pauligk, Timo Gaiser, (unknown), S-E. Al-Batran	2
7	1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK 2021 ·Annals of Oncology ·S-E. Al-Batran, Sylvie Lorenzen, Nils Homann, Peter Thuss‐Patience, Michael Schenk, Udo Lindig, A. Kretzschmar, (unknown), Eray Goekkurt, Georg Martin Haag, Jorge Riera Knorrenschild, Claus Bolling, R. D. Hofheinz, (unknown), Natsumi Irahara, Christina Kopp, (unknown), Claudia Pauligk, (unknown), Timo Gaiser	22
8	1443P Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO 2020 ·Annals of Oncology ·Claudia Pauligk, (unknown), Peter Thuss‐Patience, Jorge Riera‐Knorrenschild, Eray Goekkurt, Thomas J. Ettrich, Daniel Pink, Udo Lindig, Kim Barbara Luley, Tobias Dechow, Michael Bitzer, Stefan Angermeier, Nils Homann, Frank Kullmann, Gunter Schuch, Claus Bolling, (unknown), Ralf‐Dieter Hofheinz, Sylvie Lorenzen, S-E. Al-Batran	6
9	LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study 2020 ·Annals of Oncology ·Ken Kato, (unknown), Manan Shah, Peter C. Enzinger, Antoine Adenis, Toshihiko Doi, Takashi Kojima, J-P. Metges, Zhouxiao Li, S-B. Kim, (unknown), Wasat Mansoor, SH Li, Patrapim Sunpaweravong, María Maqueda, Eray Goekkurt, (unknown), Sukrut Shah, Pooja Bhagia, Lin Shen	98
10	1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM 2020 ·Annals of Oncology ·S-E. Al-Batran, Ralf‐Dieter Hofheinz, Harald Schmalenberg, Dirk Strumberg, Eray Goekkurt, Stefan Angermeier, Thomas Zander, Jochem Potenberg, H-G. Kopp, Daniel Pink, Gabriele Margareta Siegler, Michael Schenk, F. De Vita, Evaristo Maiello, Timo Gaiser, Disorn Sookthai, (unknown), Claudia Pauligk, (unknown), Nils Homann	5
11	1499TiP FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy – The phase II/III RAMIRIS study 2020 ·Annals of Oncology ·S-E. Al-Batran, (unknown), Tobias Dechow, Eray Goekkurt, Hana Algül, Thomas Decker, (unknown), Ralf‐Dieter Hofheinz, Markus Möhler, M. Stahl, Peter Thuss‐Patience, (unknown), Claudia Pauligk, Sylvie Lorenzen	0
12	1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma 2020 ·Annals of Oncology ·S-E. Al-Batran, (unknown), Thomas J. Ettrich, K Borchert, A. Kretzschmar, Christian Teschendorf, Gabriele Margareta Siegler, (unknown), Eray Goekkurt, Manfred Welslau, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf O. Bechstein, Peter Reichardt, Timo Gaiser, Disorn Sookthai, Claudia Pauligk, Thorsten Oliver Goetze, Ralf‐Dieter Hofheinz	15
13	Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study 2019 ·Annals of Oncology ·Josep Tabernero, Eric Van Cutsem, Yung‐Jue Bang, Charles S. Fuchs, Lucjan Wyrwicz, Kyoung Bun Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, (unknown), (unknown), Maria Ignez Braghiroli, Eray Goekkurt, Joseph Chao, Zev A. Wainberg, Uma Kher, Sukrut Shah, Soonmo Peter Kang, Kohei Shitara	16
14	Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO) 2015 ·Annals of Oncology ·Johan Vansteenkiste, Fabrice Barlési, Cornelius F. Waller, Jaafar Bennouna, Cesare Gridelli, Eray Goekkurt, Didier Verhoeven, Aleksandra Szczęsna, (unknown), Janusz Milanowski, Paul Germonpré, H. Léna, Djordje Atanackovic, Maciej Krzakowski, Christine Hicking, J. Sträub, Martin Picard, Wolfgang Schuette, Kenneth J. O’Byrne	64
15	Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity 2013 ·International Journal of Hematology ·Lars Harbaum, Andreas H. Marx, Eray Goekkurt, Philippe Schafhausen, Djordje Atanackovic	10
16	Prognostic role of microRNA polymorphisms in advanced gastric cancer: a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) 2013 ·Annals of Oncology ·(unknown), Jan Stoehlmacher-Williams, Salah‐Eddin Al‐Batran, N Heussen, (unknown), Claudia Pauligk, Sylvia Lehmann, Tina Senff, Ralf‐Dieter Hofheinz, Gerhard Ehninger, Michael Krämer, Eray Goekkurt	36
17	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial breakdown → 2009 ·The Lancet Oncology ·Gunnar Folprecht, Thomas Gruenberger, Wolf O. Bechstein, Hans-Rudolf Raab, Florian Lordick, Jörg T. Hartmann, Hauke Lang, Andrea Frilling, Jan Stoehlmacher, Jürgen Weitz, Ralf Konopke, Christian Stroszczynski, Torsten Liersch, (unknown), Thomas Herrmann, Eray Goekkurt, Fabio Parisi, Claus‐Henning Köhne	671
18	Graft-versus-Host disease Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy: Results of the EVTAC Trial 2009 ·Biology of Blood and Marrow Transplantation ·Uwe Platzbecker, Malte von Bonin, Eray Goekkurt, (unknown), (unknown), Alexander Kiani, Jan Stoehlmacher, Johannes Schetelig, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser	39
19	Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) – novel predictors for response and survival in gastric cancer patients 2005 ·British Journal of Cancer ·Eray Goekkurt, (unknown), Christine Wolschke, Corinna Wittmer, (unknown), Dieter K. Hossfeld, Jan Stoehlmacher	101
20	Pharmacogenetics of Extraordinary Responses to 5-FU/Cisplatin Chemotherapy in Advanced Gastric Cancer – Report of 2 Cases 2005 ·Oncology Research and Treatment ·Christine Wolschke, Eray Goekkurt, Salah‐Eddin Al‐Batran, Dieter K. Hossfeld, Jan Stoehlmacher	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact